SQLite Web: event_store.db

Update row 13576 in events

seq

Primary key. INTEGER

id

TEXT NOT NULL

kind

TEXT NOT NULL

ts

TEXT NOT NULL

actor

TEXT

subject_entity_ids

TEXT

payload

{"created_at":"2026-04-10T03:04:31.796915+00:00","dedupe_key":"signal_enriched:discovery_sec_filing_delta:173bbb6b0467a25d","evidence_event_ids":["evt_a3c3e46dcd78"],"signal_type":"discovery_sec_filing_delta","source":"discovery_sec_filings","value":{"aggregator_url":"https://www.sec.gov/Archives/edgar/data/1000697/0001193125-26-149657.txt","as_of":"2026-04-10T03:04:31.796915+00:00","canonical_url":"https://www.sec.gov/Archives/edgar/data/1000697/0001193125-26-149657.txt","company":"WATERS CORP /DE/","enrichment":{"aggregator_url":"https://www.sec.gov/Archives/edgar/data/1000697/0001193125-26-149657.txt","article_chars":5000,"article_truncated":true,"blocked_reason":null,"candidate_id":"sc_e1409ea0847b133d","canonical_host":"sec.gov","canonical_is_aggregator":false,"canonical_url":"https://www.sec.gov/Archives/edgar/data/1000697/0001193125-26-149657.txt","content_type":"text/plain","enriched_at":"2026-04-10T03:13:53.285532+00:00","extraction_method":"heuristic","fetched_description":"","fetched_title":"DEF 14A","final_url":"https://www.sec.gov/Archives/edgar/data/1000697/0001193125-26-149657.txt","html_truncated":true,"paywall_likely":false,"publisher_domain":"sec.gov","publisher_resolution":"canonical_url","requested_url":"https://www.sec.gov/Archives/edgar/data/1000697/0001193125-26-149657.txt","source_event_id":"evt_a3c3e46dcd78","source_quality":"high","status_code":200,"version":"signal_enrichment_v2"},"form_type":"DEF 14A","fp":"ceb9c5dfc0408437","kind":"sec_filing","published_at":"20260409","publisher_domain":"sec.gov","signal_understanding":{"analysis_basis":"article","claim_confidence":0.72,"dates_mentioned":["2026-04-09","2026","2025","2024","2023","2022","2021"],"entities":[{"asset_class":"equity","name":"Waters Corporation","relevance":"high","symbol":"","type":"issuer"},{"asset_class":"other","name":"BD (Becton, Dickinson)","relevance":"high","symbol":"","type":"acquired_business_reference"},{"asset_class":"other","name":"Waters Board of Directors","relevance":"medium","symbol":"","type":"governance_body"}],"event_type":"listing","information_gaps":["The provided text does not include the full DEF 14A itemized agenda (e.g., specific proposals, director nominees, voting matters) beyond the introductory letter and governance/integration themes.","The provided text does not specify the exact \u201cAmendment No.\u201d value (shown as blank: \u201c(Amendment No. )\u201d).","The provided text does not provide detailed financial figures or quantified transaction terms (e.g., purchase price, expected financial impact).","The provided text does not state what specifically changed versus a prior known state (no prior filing text/delta content was provided)."],"key_facts":["SEC filing type: Definitive Proxy Statement (DEF 14A) under Schedule 14A.","Issuer: Waters Corporation (Name of registrant as specified in its charter).","Filing date shown in provided context: April 9, 2026 (\"Filed 20260409\" / \"April 9, 2026\" letter date).","The letter states Waters delivered \u201cindustry-leading financial results\u201d and took a \u201csignificant step\u201d toward becoming a global life sciences and diagnostics leader through the acquisition of BD\u2019s Biosciences & Diagnostic Solutions businesses.","The Board \u201crigorously evaluated the transaction\u201d and continues to oversee integration to capture opportunities.","Post-transaction, Waters strengthened the Board with expertise aligned to expanded business areas including genomics, infectious diseases, and molecular diagnostics.","The filing states Waters\u2019 Board has 11 members and references experience across global markets, science and technology, manufacturing, and strategic planning.","The filing states 2026 priorities include disciplined oversight of integration (including risk mitigation and regulatory considerations), robust human capital management across an approximately 16,000-person global workforce, and continued shareholder engagement/solicitation of feedback."],"numeric_claims":[{"label":"Board size (members)","value":"11"},{"label":"Global workforce (approx.)","value":"16,000"}],"primary_claim":"Waters Corporation filed a definitive proxy statement (DEF 14A) on April 9, 2026.","relevance_score":0.55,"sentiment":"mixed","source_quality":"high","summary":"Waters Corporation filed a definitive proxy statement on Form DEF 14A on April 9, 2026. The filing discusses governance/Board refreshment and priorities for integrating the acquisition of BD\u2019s Biosciences & Diagnostic Solutions businesses.","topics":["SEC filing","proxy statement","corporate governance","Board refreshment","acquisition integration","human capital management","shareholder engagement"]},"source":"sec_edgar","source_domain":"sec.gov","summary":"Form DEF 14A \u00b7 WATERS CORP /DE/ \u00b7 Filed 20260409","ticker":"WAT","tickers":["WAT"],"title":"WAT filed DEF 14A","url":"https://www.sec.gov/Archives/edgar/data/1000697/0001193125-26-149657.txt"}}

TEXT NOT NULL

source_ref

TEXT

confidence

REAL (default 0.0

dedupe_key

TEXT

episode_id

TEXT

created_at

TEXT NOT NULL (default strftime('%Y-%m-%dT%H:%M:%fZ','now')

Cancel